KR20240133746A - 다중특이적 작제물 및 이의 용도 - Google Patents

다중특이적 작제물 및 이의 용도 Download PDF

Info

Publication number
KR20240133746A
KR20240133746A KR1020247026895A KR20247026895A KR20240133746A KR 20240133746 A KR20240133746 A KR 20240133746A KR 1020247026895 A KR1020247026895 A KR 1020247026895A KR 20247026895 A KR20247026895 A KR 20247026895A KR 20240133746 A KR20240133746 A KR 20240133746A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
antibody
sdab
cldn6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247026895A
Other languages
English (en)
Korean (ko)
Inventor
원칭 지앙
지앤 리
시 천
얜 리우
빙스 구오
Original Assignee
아이-맵 바이오파마 컴파니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이-맵 바이오파마 컴파니 리미티드 filed Critical 아이-맵 바이오파마 컴파니 리미티드
Publication of KR20240133746A publication Critical patent/KR20240133746A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247026895A 2022-01-09 2023-01-09 다중특이적 작제물 및 이의 용도 Pending KR20240133746A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/070870 2022-01-09
CN2022070870 2022-01-09
CN2022117334 2022-09-06
CNPCT/CN2022/117334 2022-09-06
PCT/CN2023/071334 WO2023131329A1 (en) 2022-01-09 2023-01-09 Multispecific constructs and uses thereof

Publications (1)

Publication Number Publication Date
KR20240133746A true KR20240133746A (ko) 2024-09-04

Family

ID=87073282

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247026895A Pending KR20240133746A (ko) 2022-01-09 2023-01-09 다중특이적 작제물 및 이의 용도

Country Status (9)

Country Link
US (1) US20250074995A1 (enExample)
EP (1) EP4460527A4 (enExample)
JP (1) JP2025501372A (enExample)
KR (1) KR20240133746A (enExample)
CN (1) CN119173539A (enExample)
AU (1) AU2023205989A1 (enExample)
CA (1) CA3248088A1 (enExample)
MX (1) MX2024008500A (enExample)
WO (1) WO2023131329A1 (enExample)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
US11739136B2 (en) * 2019-03-18 2023-08-29 Innovative Cellular Therapeutics Holdings, Ltd. Inducible dominant negative PD-1 and uses in adoptive cell therapy
EP3816185A1 (en) * 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
PH12022552323A1 (en) * 2020-03-31 2023-12-04 Chugai Pharmaceutical Co Ltd Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
EP4138864A4 (en) * 2020-04-23 2024-07-10 Innovative Cellular Therapeutics Holdings, Ltd. Polyspecific binding molecules and their use in cell therapy
WO2021247474A1 (en) * 2020-06-02 2021-12-09 H. Lee Moffitt Cancer Center And Research Institute Inc. Sstr-binding chimeric antigen receptors
CN117355540A (zh) * 2021-05-21 2024-01-05 百济神州有限公司 抗cd137抗体和使用方法
CA3230426A1 (en) * 2021-09-03 2023-03-09 Novarock Biotherapeutics, Ltd. Bispecific binding proteins that bind cd137 and a tumor associated antigen

Also Published As

Publication number Publication date
WO2023131329A1 (en) 2023-07-13
CN119173539A (zh) 2024-12-20
EP4460527A4 (en) 2026-03-11
JP2025501372A (ja) 2025-01-17
CA3248088A1 (en) 2023-07-13
EP4460527A1 (en) 2024-11-13
MX2024008500A (es) 2024-08-26
US20250074995A1 (en) 2025-03-06
AU2023205989A1 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
KR102839330B1 (ko) Pd-1에 대한 단일-도메인 항체 및 이의 변이체
WO2019096121A1 (en) Single-domain antibodies and variants thereof against pd-l1
JP7702961B2 (ja) 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用
KR20160006168A (ko) 인간화 항-cd134(ox40) 항체 및 이의 용도
CA3078849A1 (en) Antibodies and variants thereof against pd-l1
CN114008080B (zh) 抗pd-l1/抗lag-3多抗原结合蛋白及其使用方法
CA3079313A1 (en) Antibodies and methods of use
KR20220148209A (ko) 항cd137 작제물 및 그 용도
EP3178848A1 (en) Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
US20250074995A1 (en) Multispecific constructs and uses thereof
US20240141048A1 (en) Anti-vista constructs and uses thereof
WO2021164701A1 (en) Fusion proteins and uses thereof
WO2024051752A9 (en) Multispecific constructs and uses thereof
WO2026092728A1 (en) Anti-igf-1r antibody constructs and uses thereof
WO2023109900A1 (en) Anti-ox40 antibodies, multispecific antibodies and methods of use
US20230125301A1 (en) Multispecific anti-claudin-18.2 constructs and uses thereof
EP4584296A1 (en) Anti-vista constructs and uses thereof
HK40108627A (zh) 抗vista的构建体及其用途
HK40082022A (en) Anti-cd137 constructs, multispecific antibody and uses thereof
HK40079270A (en) Anti-cd137 construct and use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000